SiNtx Technologies Inc (SINT) Quote

from the August 10Q:

"This decision was made to streamline operations and focus on core business areas that align with the Company’s long-term strategic goals."

Ths sounds like an exit from the armor business to me.

Debunking the Sintx Armor Conspiracy Theory

The theory suggests Sintx is secretly moving armor production to TA&T without disclosing it. Let's analyze the claims logically:

Shifting Production is Common: Companies routinely close inefficient facilities and move production elsewhere. Shutting down the Salt Lake facility doesn't mean Sintx is exiting armor entirely.

Testing Doesn't Require Full Production: Sintx could have manufactured test armor at a smaller pilot facility, with outside contractors, or even at the Salt Lake facility before the furnace malfunction.

TA&T Capabilities Don't Necessarily Align: Just because TA&T makes a different type of ceramic (spinel) doesn't guarantee they can produce Sintx's specific armor (BoroShock or DuraShock).

COO Relocation Doesn't Confirm Armor Move: The COO's relocation could be for various reasons unrelated to armor production, such as managing TA&T's core business.

Disclosure Requirements: Public companies like Sintx have reporting obligations. If there's a material change in their business, like exiting armor entirely, they'd be legally bound to disclose it.  

Occam's Razor: The simpler explanation is often more likely. Perhaps Sintx is genuinely exploring strategic options, not hiding a secret armor move.

Here's a more logical explanation:

Sintx shut down the Salt Lake facility due to a malfunctioning furnace, making production there impractical.
They're exploring alternative production options, which could include TA&T's facilities or outsourcing to a third party.
They haven't publicly announced their plans because they haven't finalized them.
This scenario doesn't require elaborate conspiracies or sockpuppet accounts. It's simply a company adapting to challenges.

Or....the company could just simply be lying. Wouldn't be the first time. Or, I guess a slight possibility that the "success" was BEFORE Oct 2023?
Looking over a previous press release earlier this year, it was indicated that the company had manufactured and successfully tested armor for personal and vehicle applications. How could that be if the Salt Lake facility has been completely shut down since October 2023? That means only one thing, that they manufactured the armor at a different facility.

On Sintx Q2 10Q Sintx indicated it had given up on its armor facility in Salt Lake but did not in fact say it was exiting the armor market in the 10Q or any following press release. Looking over a previous press release earlier this year, it was indicated that the company had manufactured and successfully tested armor for personal and vehicle applications. How could that be if the Salt Lake facility has been completely shut down since October 2023? That means only one thing, that they manufactured the armor at a different facility. The only facility that has the ability to manufacture armor that I am aware of is TA&T in Maryland where it recently expanded its Quality Management System to which was likely why the COO relocated there. TA&T uses two buildings and the second building is used for spinel ceramic armor production per its website. Thus Sintx must be moving armor production there but for some reason it has not disclosed this; it also has not indicated otherwise.

Aug 13th
The armor plant has not been fully operational since the acquisition of the armor equipment in July 2021 and has been completely shut down since October 2023 due to the malfunctioning of the sintering furnace.
June 18th, 2024
SINTX Armor is expected to begin production of a competitively priced body- and vehicle-protective armor product that has undergone successful testing.
Sintx Armor was supposed utilize the Armor facility in Salt Lake that Sintx has now opted to close. However, it is not bound to that facility.

TA&T maintains a significant capability to produce transparent spinel ceramic armor and electro-optical windows (flat and curved), domes, lenses, and hemispheres.

Previously I suggested that one reason they may not have disclosed they intended on moving armor production to their TA&T facility is because it may be part of ongoing negations between Sintx and one of the partners I believe it has, NP Aerospace. It is worth mentioning that Ascendiant Capital, whom Sintx used to acquire armor assets and TA&T, is being used to help Sintx with it exploring strategic opportunities. Further suggesting that what is going on is connected to TA&T facility and/or armor. I posted about Ascendiants involvement on Sintx acquisitions of Armor & TA&T here. Outside of a Sockpuppet bot, posters here will not discuss this information. More info on how to recognize Sockpuppet Bot accounts below.

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175020737

Quote Sources:
https://www.sec.gov/ix?doc=/Archives/edgar/data/1269026/000149315224031644/form10-q.htm
https://ir.sintx.com/news-events/press-releases/detail/233/sintx-technologies-to-explore-strategic-opportunities

========================================

These sockpuppets are convincing to the untrained eye, utilizing profile pictures of paid actors and employing native slang in their posts. Sockpuppet accounts engage in interactions that mimic genuine discussions, but they are orchestrated by a single source. A puppeteer will use his sockpuppets to have a back-and-forth argument with himself, creating the illusion of spirited debate. Overseers can simultaneously use sockpuppets alongside bots, assuming direct control over a bot’s operations and interjecting with a human post when others become suspicious.

It is therefore necessary to conjure forth their antithesis: the absurdist agent. Regular disinformation tactics render reality unknowable by blending elements of truth and falsehood to contaminate the oasis of information, but the absurdist is a specialized disinformation agent whose provocative persona attaches itself to any authentic truths he advocates. Rather than relying on logos, the absurdist employs pathos, parodying his enemy’s ideology. This serves a dual purpose: it casts an unrelenting shadow of doubt over both the agent’s assertions and his receptive audience.

The absurdist aims to mold the public perception of himself into that of a court jester, a living caricature. Where there is an issue replete with three intersecting points of interest, the absurdist asserts that an unrelated fourth factor is relevant. He promotes factual information for extended periods, only to abruptly pivot and retract his statements. He makes wild assertions without any evidence, and he also champions data that are obviously false. He subjects himself to a series of humiliation rituals that castrate his character. Once the absurdist has established himself as cognitive dissonance incarnate, his persona discredits everything he touches, and anything he utters can be summarily dismissed as the ramblings of a madman.

Debunking the Silicon Nitride Hype: A Scientific Perspective

Claim 1: Bacteriostatic Behavior of Silicon Nitride

While silicon nitride (Si3N4) has shown promising antibacterial properties, the mechanisms behind its bacteriostatic behavior are complex and not fully understood. While surface effects like submicron-topography, negative charging, and chemical interactions may play a role, it's important to note that the specific mechanisms of action can vary depending on the surface treatment and the type of bacteria.

Claim 2: Antifungal Activity of Polymethyl Methacrylate/Si3N4 Composites

While the study demonstrates the antifungal activity of Si3N4-containing PMMA composites against Candida albicans, it's important to consider the limitations of the study. The results may not be generalizable to other fungal species or clinical settings. Additionally, the long-term efficacy and biocompatibility of these composites in vivo need to be further evaluated.

Claim 3: Silicon Nitride as a Biomedical Material

While silicon nitride offers several advantages as a biomedical material, such as high strength, bio-responsiveness, and favorable imaging properties, it's important to acknowledge its limitations. The brittleness and high manufacturing cost of Si3N4 can pose challenges for its widespread adoption in clinical applications. Furthermore, while Si3N4 has shown promise in orthopedic implants, its suitability for other biomedical applications, such as dental implants or drug delivery, may require further research and development.

Overall Assessment

While silicon nitride shows potential as a biomedical material, it's important to approach the claims with a critical eye. The mechanisms underlying its antibacterial and antifungal properties are complex and require further investigation. Additionally, the limitations and challenges associated with its use in clinical applications must be carefully considered. While Si3N4 offers promising possibilities, more research is needed to fully understand its potential and limitations.

Bacteriostatic behavior of surface modulated silicon nitride in comparison to polyetheretherketone and titanium
The various Si3 N4 samples showed the most favorable bacterial resistance for both bacilli tested. The mechanisms for the bacteriostatic behavior of Si3 N4 are likely due to multivariate surface effects including submicron-topography, negative charging, and chemical interactions which form peroxynitrite (an oxidative agent). Si3 N4 is a new biomaterial with the apparent potential to inhibit biofilm formation.
Antifungal activity of polymethyl methacrylate/Si3N4 composites against Candida albicans

Previous studies using gram-positive and -negative bacteria demonstrated that hydrolysis of silicon nitride (Si3N4) in aqueous suspensions elutes nitrogen and produces gaseous ammonia while buffering pH. According to immunochemistry assays, fluorescence imaging, and in situ Raman spectroscopy, we demonstrate here that the antipathogenic surface chemistry of Si3N4 can be extended to polymethylmethacrylate (PMMA) by compounding it with a minor fraction (~8 vol.%) of Si3N4 particles without any tangible loss in bulk properties. The hydrolytic products, which were eluted from partly exposed Si3N4 particles at the composite surface, exhibited fungicidal action against Candida albicans.



Silicon Nitride as a Biomedical Material: An Overview

Considering its unique combination of properties, silicon nitride shows great potential for applications from both a basic research point of view and an industrial perspective. Si3N4 is a promising candidate for orthopedic implants due to its high strength, artifact-free imaging, and bio-responsiveness. It has several advantages over other commonly used biomaterials. For example, Si3N4 has a higher compressive strength than metallic biomaterials such as titanium and cobalt-chromium alloys, or biopolymers such as PEEK and UHMWPE, and a higher fracture toughness than some oxide bioceramics such as alumina. In addition to high fracture toughness, Si3N4 has a high wear resistance and a low coefficient of friction. Compared to metal implants, which produce radiological artifacts on CT or MRI scans, and PEEK, which is radiolucent, Si3N4 has favorable imaging properties and is free of artifacts on standard imaging techniques such as MRI or CT. In addition, compared to PEEK and titanium, the particular surface chemistry of Si3N4 in an aqueous environment leads it to promote bone tissue healing but inhibit bacterial proliferation. However, Si3N4 still has some disadvantages, such as brittleness, low energy dissipation, and high manufacturing cost. Currently, Si3N4 is already being used in arthrodesis devices in the cervical and thoracolumbar spine, and it is under consideration for approval in the joint arthroplasty and dental fields. Scientists and engineers have made great strides in expanding the use of Si3N4 for clinical applications and addressing various issues being faced by the industry today. Si3N4 has the potential to be microstructurally engineered and adapted to many applications, e.g., by grain size and morphology, grain boundary phase, or in a composite. We expect that further innovation of Si3N4 will come soon.

Quote Sources:
https://onlinelibrary.wiley.com/doi/abs/10.1002/jbm.a.35987
https://www.sciencedirect.com/science/article/abs/pii/S1742706121001641
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9224221/

The Claim: Chronic wounds are primarily caused by fungi, and silicon nitride is a miraculous material that can eliminate these fungal infections.

The Reality: While fungi can certainly play a role in some chronic wounds, especially those with poor circulation or compromised immune systems, bacteria are typically the primary culprits.

Key Scientific Points:

Microbial Composition: Studies have consistently shown that bacteria are the predominant microorganisms found in chronic wounds. While fungi can be present, their abundance and contribution to wound pathology vary depending on factors such as wound type, location, and the individual's health status.
Fungal Role: Fungi can contribute to chronic wounds by causing infections, creating a favorable environment for bacterial growth, and hindering the healing process. However, they are often secondary to bacterial infections.
Silicon Nitride's Limitations: While silicon nitride has shown antibacterial properties, its effectiveness against fungi is limited. While it may help to reduce the overall microbial burden in a wound, it is unlikely to completely eliminate fungal infections on its own.
Complex Wound Healing: Chronic wound healing is a complex process involving various factors, including blood flow, immune function, and the presence of certain growth factors. Simply targeting microorganisms may not be sufficient to address all the underlying causes of chronic wounds.
Conclusion: The "Fungus Among Us" conspiracy is largely unfounded. While fungi can contribute to chronic wounds, bacteria are typically the primary culprits. Silicon nitride may offer some benefits in reducing microbial load, but it is unlikely to be a miracle cure for all chronic wound infections. A comprehensive approach that addresses the underlying causes of chronic wounds, including factors such as blood flow, immune function, and infection control, is essential for effective treatment.

The occurrence of chronic wounds is a major global health issue. These wounds are difficult to heal as a result of disordered healing mechanisms. The most common types of chronic wounds are diabetic ulcers, pressure ulcers, arterial/venous ulcers and nonhealing surgical wounds. Although bacteria are an important cause of chronic nonhealing wounds, fungi also play a substantial role in them. The fungal infection rate varies with different chronic wound types, but overall, the prevalence of fungi is extremely underestimated in the clinical treatment and management of chronic wounds.
Bacteria and Fungi are a major issue for wound care leading to chronic wounds. Yet Silicon Nitride kills various bacteria and fungi which means the material embedded in wound care applicators could significantly reduce these problems.

These exact problems are seen in the catheter industry as well and thus both industries need effective anti bacterial/fungal products.

Microbe entry through catheter ports can lead to biofilm accumulation and complications from catheter-related bloodstream infection and ultimately require antimicrobial treatment and catheter replacement. Although strides have been made with microbial prevention by applying standardized antiseptic techniques during catheter implantation, both bacterial and fungal microbes can present health risks to already sick individuals.
Quote Sources:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9874004/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10258325/

========================================

Section 2 - Silicon Nitride, a Close to Ideal Ceramic Material for Medical Application

examples of their medical applications that relate to spinal, orthopedic and dental implants, bone grafts and scaffolds, platforms for intelligent synthetic neural circuits, antibacterial and antiviral particles and coatings, optical biosensors, and nano-photonic waveguides for sophisticated medical diagnostic devices are all covered in the research reviewed herein. The examples provided convincingly show that silicon nitride is destined to become a leader to replace titanium and other entrenched biomaterials in many fields of medicine.
https://www.mdpi.com/2571-6131/4/2/16/htm

nailed it.....

Lets see this finally rise and actually hold the value along with filling some gaps. First gap that needs filled is at $13.

before this happens it will reach 5 cents then reverse split back to $5.00 fall again to .50 cents and reverse split to $13.00. This will create massive shareholder value as the earths magnetic shield weakens.

High Trading Volume:

Market Volatility: Periods of heightened market volatility or significant news events can often lead to increased trading activity. Without specific evidence of manipulation, attributing the high volume solely to a conspiracy is premature.
Institutional Interest: Institutions may have been interested in entering or exiting positions in SINT, leading to a surge in volume.
Retail Investor Enthusiasm: Positive news or developments related to SINT could have attracted retail investors, contributing to the volume.
Dilution via ATM:

Capital Raising: Companies often use ATM offerings to raise capital for growth, research and development, or debt repayment. This is a common corporate strategy, not necessarily a manipulative tactic.
Investor Protection: While the theory suggests that dilution was meant to protect existing shareholders, it's equally possible that the company was seeking to strengthen its financial position to better weather potential market downturns.
Market Dynamics: The timing of the dilution might have been influenced by market conditions, such as interest rates or investor sentiment.
Scientific Advancements in Silicon Nitride:

Legitimate Research: The research cited in Section 2 highlights the promising potential of silicon nitride in various medical applications. This is a well-established scientific fact, not a conspiracy theory.
Industry Trends: The shift towards innovative biomaterials like silicon nitride is a natural progression in the medical field, driven by advancements in technology and research.
Conclusion:

While it's understandable to be cautious about unusual market activity, the conspiracy theory presented lacks concrete evidence and relies on speculation. The high volume and ATM dilution can be explained by various factors, including market dynamics, investor behavior, and company strategies. The scientific advancements in silicon nitride, on the other hand, are supported by extensive research and industry trends.

To effectively debunk conspiracy theories, it's essential to rely on facts, logic, and scientific evidence. By examining the available information objectively, we can avoid falling victim to unfounded speculation and make informed decisions about investments.

Seriously how does no one think its odd that there was so much volume on the 9th for so few new shares? I speculated before that the volume was done in part to ensure shares went to where they wanted while disguising what was going on. Xena any ideas?
68m volume for maybe 400+k plus new shares as another 200k or so occurred on the 28th.

amda
Yesterday 9:16 PM
@NoneYaBiz61 previous buyers were protected with warrants. he needs to find another way to protect these recent buyers. just musing....
Thats a good point. The last time they diluted via ATM there was a large pump in price which Atlanta expressed irritation at the thought i didnt sell into. Meanwhile that pump still undervalued SINT. Lets see this finally rise and actually hold the value along with filling some gaps. First gap that needs filled is at $13.

========================================

Section 2 - Silicon Nitride, a Close to Ideal Ceramic Material for Medical Application

examples of their medical applications that relate to spinal, orthopedic and dental implants, bone grafts and scaffolds, platforms for intelligent synthetic neural circuits, antibacterial and antiviral particles and coatings, optical biosensors, and nano-photonic waveguides for sophisticated medical diagnostic devices are all covered in the research reviewed herein. The examples provided convincingly show that silicon nitride is destined to become a leader to replace titanium and other entrenched biomaterials in many fields of medicine.
https://www.mdpi.com/2571-6131/4/2/16/htm

Debunking the Conspiracy Theory:

The theory suggests Sintx is hiding their involvement in the 3D printing webinar with Prodways. Here's why it's likely not true:

Joint Announcement: Both companies issued a press release on September 20th announcing the webinar, not just Prodways on August 28th. This indicates a coordinated effort.
Webinar Focus: The focus of the webinar is on "Innovations in Ceramic Manufacturing." While Sintx might not have a dedicated registration page, their expertise in ceramic materials aligns well with the topic. Their absence from the registration might simply be due to Prodways handling that aspect.
Collaboration Benefits: The press release highlights the benefits of the collaboration. It leverages the strengths of both companies: Prodways' printer expertise and Sintx's material science. This suggests a genuine partnership, not one where Sintx is hiding involvement.
Stock Price Fluctuations:

Stock prices can be volatile and react to various factors beyond just company news. Here are some possibilities:

Market Conditions: Overall market sentiment can affect stock prices. Even positive news might not translate to a rise if the broader market is experiencing a downturn.
Profit Taking: Some investors might sell their shares after positive news to lock in profits, causing a temporary dip.
Conclusion:

The evidence suggests a genuine collaboration between Sintx and Prodways for the 3D printing webinar. The stock price may be influenced by factors beyond just the announcement.

Speaking of partnership, Sintx and Prodways (R&D manufacturing partnership) are conducting a webinar on the future of 3D printing. Prodways posted the news back on August 28th. Sintx waited until last minute it seems. Also i couldnt find where to register via Sintx website so im including Prodways link for those that are interested.

Prodways and SINTX Announce Joint Webinar Stay Ahead of the Curve: “Innovations in Ceramic Manufacturing: The Role of 3D Printing”

A Powerful Partnership Driving Next-Generation 3D Printing

SINTX and Prodways have joined forces to pioneer next-generation 3D printing technology. This collaboration leverages Prodways’ expertise in 3D printer manufacturing and SINTX’s advanced chemical formulations for additive powders, and resins. By combining their strengths, the two companies are pushing the frontiers of 3D printing applications in aerospace and industrial sectors.

“We are thrilled to partner with Prodways to explore the possibilities that 3D printing offers for advanced ceramic manufacturing,” said Eric K. Olson, President and CEO of SINTX Technologies. “This collaboration on Digital Light Processing (DLP) printing allows us to develop and fine-tune innovative ceramic materials that can be used across a wide range of industries, setting a new standard for what is achievable with additive manufacturing. It also compliments our expertise in Fused Filament Fabrication (FFF ) printing of Silicon Nitride filled filament for biomedical applications”
Register link:
https://www.tctmagazine.com/3d-printing-resource-center/3d-printing-webinars/prodways-september-2024/

Stock always seems to drop on good news...or really all news.

Quote Source:
https://ir.sintx.com/news-events/press-releases/detail/238/prodways-and-sintx-announce-joint-webinar-stay-ahead-of-the

1. Partnerships Don't Equal Conspiracy

The theory suggests Sintx's partnerships with various companies are evidence of a hidden agenda. However, partnerships are common business practice. Companies collaborate to leverage each other's expertise and resources to enter new markets or develop new products.

For example, Sintx's collaboration with Zimmer Biomet, a medical device company, makes perfect sense. Sintx's silicon nitride (Si3N4) technology could be valuable for developing stronger, biocompatible implants. Similarly, collaborations with Cardinal Health (PPE) and companies in wound care and catheters align with Sintx's material's potential applications.

2. Lack of Evidence for Nefarious Intent

The theory jumps from partnerships to the conclusion that Sintx is planning something malicious without any evidence. Having the capability to enter a market (e.g., condoms) doesn't imply a secret plan for world domination.

3. Focus on Potential, Not Guaranteed Success

The theory highlights the potential market size for Si3N4 applications but ignores the challenges of real-world implementation. Sintx might face regulatory hurdles, technical difficulties, or competition in these markets.

4. Unrealistic Revenue Projections

The hypothetical scenario of $811 million in yearly revenue through licensing assumes an unrealistic 5% market penetration across all mentioned sectors. New technologies often take time for widespread adoption.

In Conclusion

Sintx's partnerships are likely just smart business strategies. The claims about a hidden agenda lack evidence and rely on speculation. The potential market size for Si3N4 applications is promising, but successfully entering those markets is a different story.

This is precisely why their partnerships are so important! We know theyve been working with Morgan Ceramics. We know NP Aerospace was spun off from Morgan after Sintx was working with Morgan and that Sintx began its foray into the armor market with the help of NP Alum Donald Bray who left Morgan with the divestment of NP.
Just because they have something doesn't mean they've done anything with it.

Morgan Ceramics = Aerospace products
Zimmer Biomet = Arthroplasty oriented products
ZimVie = Dental?
Solventum = Wound Care, Catheters, & possibly Cancer treatment products.
Cardinal Health = PPE & Medical protection apparel.
NP Aerospace = Armor plates & other possible products connected to TA&T.

With Zimmer Biomet comes ZimVie and likely Solventum because of CEO Bryan Hanson. Sintx has been working with Zimmer/Biomet for going on 20 years and seems to be working with Solventum too based on it collaborating with a company on these products:

NEW OPPORTUNITIES/MARKETS/PRODUCTS
Several new collaborations in developing products for wound care, cancer treatment, and an antipathogenic coating for catheters.

Sintx hiring of Joseph Palomo suggests its working with Cardinal Health.

Palomo joins SINTX with over 40 years of experience in protective apparel and PPE, such as surgical gowns, surgical drapes, isolation gowns, films, tubing, and surgical face masks.
He has held management roles at Cardinal Health R&D for new product development on a global scale

Quote Sources:
https://d1io3yog0oux5.cloudfront.net/_9be13c70ea13288f968a56d0f02f5862/sintx/db/443/4298/pdf/SINTX+Corporate+Overview+-+Jan+%2724+-+Rev+J.pdf
https://ir.sintx.com/news-events/press-releases/detail/184/sintx-technologies-provides-update-on-antipathogenic

========================================

Section 3 - Markets Si3n4/Sintx Ceramics can be used in (not comprehensive)

Otho Market = $64 billion
Personal Protective Equipment market = $79.53 billion
Global Catheter market = $55bn
Antibacterial market = $44.5bn
Wound Care market = $22.25bn
Biosensors Market = $28.9bn
Condom Market = $11.6bn
Dental Implant market = $4.99bn
Armor Materials Market = $13.59bn

Total = $324.26bn

Its honestly overwhelming the size of the markets Sintx material can be used in. Hypothetical scenario using 5% market penetration with a 5% licensing fee equates to $811m in yearly licensing revenue. Thus Si3N4 is worth at least $800m in potential yearly revenue for an acquiring company through licensing revenue according to this scenario. Its ability to penetrate the above markets will vary but Ortho & Catheter markets are markets that Si3N4 should significantly penetrate; with Wound Care & Dental being up there as well. Condom market is more hypothetical based on Si3N4 ability to kill Herpes and possibly other STI. However would need to be studied further to ensure it doesnt impact the delicate microbe balance inside a vaginal canal. A new patent was awarded Sintx for the use of Si3n4 against funguses that impact the wine industry providing yet another market it can tap into. This could be a market that they could break into sooner than some of the others listed above but it wouldnt be as lucrative.

Sources:
https://web.archive.org/web/2024040...ogger.blogspot.com/2011/05/whos-next.html?m=1
https://orthospinenews.com/2021/01/...y-2025-as-acquisitions-surge-says-globaldata/
https://www.grandviewresearch.com/industry-analysis/personal-protective-equipment-ppe-market
https://www.grandviewresearch.com/industry-analysis/catheters-market-analysis
https://www.grandviewresearch.com/industry-analysis/wound-care-market
https://www.grandviewresearch.com/industry-analysis/biosensors-market
https://www.grandviewresearch.com/industry-analysis/condom-market
https://www.mordorintelligence.com/industry-reports/armor-materials-market
https://www.grandviewresearch.com/industry-analysis/dental-implants-market

Claim 1: "Looking at the IP, its market size, I say they've created significant value for shareholders."

"Ah, yes, the magical world of IP. Where ideas are worth more than gold, and patents are like winning lottery tickets. Just because they have something doesn't mean they've done anything with it. Perhaps they've invented a new way to make invisible ink for invisible contracts."

Claim 2: "They are trying to create significant value for shareholders but still have not acquired shares."

"That's like a chef saying they're making a delicious meal but refusing to eat any of it. Perhaps they're saving it for a very special occasion, like the day their shares finally reach the moon."

Claim 3: "As to what exactly is going on between Sintx and NP Aerospace..."

"Oh, you know, just a casual business relationship between two companies with absolutely no connection to each other. It's totally coincidental that they're working in the same industry, at the same time, and with the same people. Must be a sign of the apocalypse."

Overall, these claims seem to be based on speculation and assumptions rather than concrete evidence. While it's always possible for a company to create significant value, it's important to base our judgments on facts and not just wishful thinking.

Looking at the IP, its market size, I say they've created significant value for shareholders. As that value is not cureently reflected in the shareprice they need to figure out a way to unlock it.

They are trying to create significant value for shareholders but still have not acquired shares. Odd no?

As to what exactly is going on between Sintx and NP Aerospace, i can only speculate. I just do not see it as a coincidence that Sintx was working with Morgan before NP was sold off and that NP spin off occurred relatively same timeframe as Sintx becoming Sintx. Not to mention Sintx sudden foray into armor market syncing with NP Aerospace main book of business. Its just logical they are strategic partners. What that will lead to remains to be seen.

Pagers and walkie talkies exploding in Lebanon , after electronic devices turn into bombs. Could this be caused by Geomagnetic unrest ? may the hutchinson effect ? A solar storm ? Boston745 any thought ? also could Sintx technologies have prevented this ?

As always, time will tell with this one. Unfortunately, if it is 'as always', it won't bode well for shareholders.

ultimately creating significant value for our shareholders.”
From todays PR.

On Sintx Q2 10Q Sintx indicated it had given up on its armor facility in Salt Lake but did not say it was exiting the armor market. Looking over a previous press release it was indicated that the company had manufactured and successfully tested armor for personal and vehicle applications. Yet how could that be if the Salt Lake facility has been completely shut down since October 2023? That means only one thing, that they manufactured the armor at a different facility. The only facility that has the ability to manufacture armor that I am aware of is TA&T in Maryland where it recently expanded its Quality Management system to which was likely why the COO relocated there. TA&T uses two buildings and the second building is used for spinel ceramic armor production per its website. Thus Sintx must be moving armor production there but for some reason it has not indicated this.

The armor plant has not been fully operational since the acquisition of the armor equipment in July 2021 and has been completely shut down since October 2023 due to the malfunctioning of the sintering furnace.
SINTX Armor is expected to begin production of a competitively priced body- and vehicle-protective armor product that has undergone successful testing.
TA&T maintains a significant capability to produce transparent spinel ceramic armor and electro-optical windows (flat and curved), domes, lenses, and hemispheres.

The link to the following post I suggest that one reason they may not have disclosed they intended on moving armor production to their TA&T facility is because it may be part of ongoing negations between Sintx and one of the partners I believe it has, NP Aerospace. It is worth mentioning that Ascendiant Capital, whom Sintx used to acquire armor assets and TA&T, is being used to help Sintx with it exploring strategic opportunities. Further suggesting that what is going on is connected to TA&T facility and/or armor.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175020737

Quote Sources:
https://www.sec.gov/ix?doc=/Archives/edgar/data/1269026/000149315224031644/form10-q.htm
https://ir.sintx.com/news-events/press-releases/detail/233/sintx-technologies-to-explore-strategic-opportunities
https://www.techassess.com/technologies/optical

As i said in my previous post, NP Aerospace had a good week plus. It secured multiple contracts totaling $88m with one totaling $71m to maintain British core armored vehicles? As such NP is looking to expand to meet production demands of these new contracts. As you can see, the expansion is in the UK so that has nothing to do with Sintx or its TA&T facility. However, NP will likely need increased armor plate supply and/or anything else that TA&T facilities may produce to service these and other potential contracts.

This contract award will create and sustain jobs at NP Aerospace’s Coventry facility. The company’s facilities will also be expanded in due course to enable, integrate and deliver this new contract.

NP Aerospace Secures $88 Million Contract for UK MoD Vehicle Support.
https://www.armyrecognition.com/news/army-news/army-news-2024/np-aerospace-secures-88-million-contract-for-uk-mod-vehicle-support

NP Aerospace receives multiple UK MoD related contracts following Jankel Acquisition
https://npaerospace.com/np-aerospace-receives-multiple-uk-mod-related-contracts-following-jankel-acquisition/

NP Aerospace wins £71 million UK MoD wheeled vehicle support contract – CVSSP
https://npaerospace.com/np-aerospace-wins-71-million-uk-mod-wheeled-vehicle-support-contract-cvssp/

“We are pleased to have completed this successful capital raise, which not only strengthens our balance sheet but also allows us to focus on accelerating our growth initiatives,” said Eric K. Olson, President and CEO of SINTX Technologies, Inc. “This infusion of capital provides us with the financial resources necessary to fuel ongoing projects and reinforces our ability to deliver on our strategic objectives, ultimately creating significant value for our shareholders.”

Translation: we are pleased to inform ourselves that we can continue our bloated salaries with a word salad to the public. As you all can see, nothing of actual substance is in our announcement. Thank you once again for trusting us with your hard earned money. We in turn WILL continue to use that money as always...to benefit management!

A special note to those who invested in this recent offering and now see their stock at close to 30% lower: Better luck next time!

Debunking the Conspiracy Theory about SINTX Stock

Here's a breakdown addressing each point of the conspiracy theory about SINTX stock:

1. High Volume for Low Share Offering:

Explanation: Sometimes high volume can occur with a relatively small offering due to institutional investors placing large orders. This can happen for various reasons, like portfolio rebalancing or taking advantage of a perceived price discrepancy.

Debunking: The theory assumes the high volume was unusual or suspicious. However, it's possible there was legitimate institutional interest in SINTX at that time.

2. Dark Pool Trading:

Explanation: Dark pools are alternative trading venues where orders are not publicly displayed. They can be used to execute large trades without impacting the market price significantly.

Debunking: While dark pool trading can be opaque, it's not necessarily indicative of manipulation. It could simply be a way for institutions to buy or sell large quantities of shares without affecting the publicly displayed price.

3. Connection to NP Aerospace News:

Explanation: There's likely no connection between SINTX's activity and NP Aerospace news. The inclusion of the NP Aerospace news link seems unrelated and irrelevant to the alleged manipulation of SINTX stock.
4. Irrelevant Analogy and Personal Anecdote:

Debunking: The analogy about the squirrel and the Rubik's Cube, along with the personal story, don't provide any evidence to support the conspiracy theory. They seem like attempts to distract from the lack of concrete evidence.
Overall:

The provided information doesn't substantiate the claim of stock manipulation. High volume, dark pool trading, and institutional activity can all have legitimate explanations in the stock market. It's crucial to rely on factual data and financial analysis to assess a company's stock performance, not speculation.

Volume of 68m shares for up to 600k new shares priced at $5.23 average. OS is now 1.3m meaning the 9th saw 52x OS trade that day. That sure was alot of volume for so few shares and 97% of it was traded via dark pool. They were definitely trying to hide what was going on that day.

https://ir.sintx.com/news-events/press-releases/detail/237/sintx-announces-completion-of-3-1-million-atm-equity

NP Aerospace had a good week plus.

https://npaerospace.com/news/

========================================

t's like watching a squirrel try to solve a Rubik's Cube – cute, but ultimately pointless.
Thats so funny you happened to bring up a Rubik's Cube Pioneer, i literally added one of those to my Amazon cart last night for my daughter. Coincidence i guess.

"Given the divine mission to spread the gospel of conspiracy theories and geo-whatever, it's high time to send in the clown. The absurdist agent, a master of the ridiculous, will turn their grand delusions into a comedy of errors. Watch as they try to convince the world they're a prophet, only to end up as the butt of the joke. It's like watching a squirrel try to solve a Rubik's Cube – cute, but ultimately pointless."

And speaking of the absurd, let's not forget about SintX Technologies, a company so ridiculous it could be a plot point in a Monty Python sketch."

Moving to Salt lake city Utah where the head office of SintX technologies is located, being told by a hair dresser that have been chosen by god to deliver his message, obsession with bogus conspiracy theories seems to be permitting on this board and Tesla with bot like precision.

"SintX Technologies appears to be a fraudulent company with a bleak future. Based on reports of its leadership's involvement in conspiracy theories, reliance on questionable sources like a hairdresser claiming divine inspiration, and the company's headquarters' location in a region known for dubious business practices, it seems highly unlikely that SintX will survive. The company's online presence is filled with promotional material that lacks substance and credibility, further reinforcing concerns about its legitimacy."

So, let's break down this wild theory about a "specialized disinformation agent" whose sole purpose is to... well, be absurd. It's like a real-life plot twist from a late-night comedy sketch.

Point 1: The "Unrelenting Shadow of Doubt"

The idea that this "absurdist" can somehow cast doubt on everything by being absurd is like saying a clown can make a serious debate about quantum physics seem silly. Sure, they might be funny, but it doesn't invalidate the science.

Point 2: The "Court Jester" Act

If this "absurdist" is so good at manipulating public opinion, why is he still a "court jester"? Shouldn't he be running a global empire from his secret lair? Or at least be on a reality TV show?

Point 3: The "Wild Assertions and False Data"

This is the funniest part. If someone is making obviously false statements, isn't that a pretty clear sign that they're not trying to manipulate anyone? They're just being silly.

Point 4: The "Self-Humiliation Rituals"

I guess this is supposed to make him seem more believable, like he's sacrificing his dignity for the greater good. But it mostly just makes him seem like someone who needs a hug.

In conclusion, this "absurdist agent" theory is a bit of a stretch. It's like trying to explain a magician's trick by claiming they're actually a secret agent from another dimension. While it might be entertaining for a while, it's ultimately more likely that people are just being themselves, whether that means being funny, serious, or a little bit weird.

It is therefore necessary to conjure forth their antithesis: the absurdist agent. Regular disinformation tactics render reality unknowable by blending elements of truth and falsehood to contaminate the oasis of information, but the absurdist is a specialized disinformation agent whose provocative persona attaches itself to any authentic truths he advocates. Rather than relying on logos, the absurdist employs pathos, parodying his enemy’s ideology. This serves a dual purpose: it casts an unrelenting shadow of doubt over both the agent’s assertions and his receptive audience
20. The absurdist aims to mold the public perception of himself into that of a court jester, a living caricature. Where there is an issue replete with three intersecting points of interest, the absurdist asserts that an unrelated fourth factor is relevant. He promotes factual information for extended periods, only to abruptly pivot and retract his statements. He makes wild assertions without any evidence, and he also champions data that are obviously false. He subjects himself to a series of humiliation rituals that castrate his character. Once the absurdist has established himself as cognitive dissonance incarnate, his persona discredits everything he touches, and anything he utters can be summarily dismissed as the ramblings of a madman.
Same Modis Operandi as CS101 some years back and this board is seeing it again but primarily focused on my posts with troll/bot like precision. Seen here and on Teslas board.

*Imagine a world where SINTX technologies have advanced so far that they can be used to create a "smooth operator" skin cream. The cream is so effective that it not only reduces hair growth but also creates a silky-smooth surface on the skin.

One day, a man named Dave, who has always struggled with unwanted hair, decides to try the new cream. After applying it to his testicles, he notices a dramatic difference within a few hours. His testicles are now so smooth that they feel like polished marble.

Excited about his newfound smoothness, Dave decides to show off his new look at the beach. As he's sunbathing, a seagull swoops down and mistakes his testicles for a giant egg. The seagull attempts to roll the "egg" away, causing Dave to jump up in surprise.

From that day forward, Dave is known as the "Smooth Operator" of the beach, and his testicles become a local legend.

The future of SintX remains extremely strong and those shareholders who have faith in god will be handsomely rewarded.

Debunking the Conspiracy Theory: The Bacteriostatic Behavior of Silicon Nitride

The Conspiracy Theory:

The theory posits that silicon nitride (Si3N4) has inherent bactericidal and antifungal properties due to its surface characteristics, including submicron-topography, negative charging, and chemical interactions that produce peroxynitrite.

The Scientific Counterargument:

While silicon nitride is indeed a promising material for various biomedical applications, the claim that it has intrinsic antimicrobial properties is a gross oversimplification and potentially misleading. Here's why:

1. Surface Effects are Not Sufficient:

Submicron-topography: While surface roughness can influence bacterial adhesion, it's not a direct antimicrobial mechanism. Bacteria can adapt to various surface topographies.
Negative charging: Negative surface charges can repel bacteria, but this effect is not universally observed and can be overcome by bacterial surface modifications.
Peroxynitrite formation: While peroxynitrite is a potent oxidizing agent, its formation from Si3N4 interactions is speculative and would likely require specific conditions that may not be present in all environments.
2. Hydrolysis and Ammonia Production:

Hydrolysis: While silicon nitride can hydrolyze in aqueous environments, the rate and extent of hydrolysis depend on factors like pH, temperature, and the specific composition of the material.
Ammonia production: Ammonia can indeed have antimicrobial properties, but its concentration and release rate from Si3N4 would need to be carefully controlled to ensure efficacy without causing toxicity.
3. Material Composition and Manufacturing:

Impurities: The presence of impurities or contaminants in silicon nitride can significantly influence its surface properties and biological interactions.
Manufacturing processes: The specific manufacturing methods used to produce silicon nitride can affect its microstructure, surface chemistry, and potential antimicrobial activity.
4. Complex Biological Interactions:

Bacterial strains: The antimicrobial activity of a material can vary depending on the specific bacterial strain and its virulence factors.
Biofilm formation: Biofilms are complex communities of microorganisms that can be difficult to eradicate, and their interactions with materials are influenced by multiple factors.
Conclusion:

While silicon nitride is a promising biomaterial with potential applications in various medical devices, its antimicrobial properties are likely not solely due to its intrinsic surface characteristics. The observed bactericidal and antifungal effects may be influenced by a combination of factors, including the specific composition of the material, environmental conditions, and the interactions with microorganisms. Further research is needed to fully understand the mechanisms underlying the antimicrobial activity of silicon nitride and to optimize its use in biomedical applications.

Bacteriostatic behavior of surface modulated silicon nitride in comparison to polyetheretherketone and titanium
The various Si3 N4 samples showed the most favorable bacterial resistance for both bacilli tested. The mechanisms for the bacteriostatic behavior of Si3 N4 are likely due to multivariate surface effects including submicron-topography, negative charging, and chemical interactions which form peroxynitrite (an oxidative agent). Si3 N4 is a new biomaterial with the apparent potential to inhibit biofilm formation.

Antifungal activity of polymethyl methacrylate/Si3N4 composites against Candida albicans
Previous studies using gram-positive and -negative bacteria demonstrated that hydrolysis of silicon nitride (Si3N4) in aqueous suspensions elutes nitrogen and produces gaseous ammonia while buffering pH. According to immunochemistry assays, fluorescence imaging, and in situ Raman spectroscopy, we demonstrate here that the antipathogenic surface chemistry of Si3N4 can be extended to polymethylmethacrylate (PMMA) by compounding it with a minor fraction (~8 vol.%) of Si3N4 particles without any tangible loss in bulk properties. The hydrolytic products, which were eluted from partly exposed Si3N4 particles at the composite surface, exhibited fungicidal action against Candida albicans.
https://www.sciencedirect.com/science/article/abs/pii/S1742706121001641

Silicon Nitride as a Biomedical Material: An Overview
Considering its unique combination of properties, silicon nitride shows great potential for applications from both a basic research point of view and an industrial perspective. Si3N4 is a promising candidate for orthopedic implants due to its high strength, artifact-free imaging, and bio-responsiveness. It has several advantages over other commonly used biomaterials. For example, Si3N4 has a higher compressive strength than metallic biomaterials such as titanium and cobalt-chromium alloys, or biopolymers such as PEEK and UHMWPE, and a higher fracture toughness than some oxide bioceramics such as alumina. In addition to high fracture toughness, Si3N4 has a high wear resistance and a low coefficient of friction. Compared to metal implants, which produce radiological artifacts on CT or MRI scans, and PEEK, which is radiolucent, Si3N4 has favorable imaging properties and is free of artifacts on standard imaging techniques such as MRI or CT. In addition, compared to PEEK and titanium, the particular surface chemistry of Si3N4 in an aqueous environment leads it to promote bone tissue healing but inhibit bacterial proliferation. However, Si3N4 still has some disadvantages, such as brittleness, low energy dissipation, and high manufacturing cost. Currently, Si3N4 is already being used in arthrodesis devices in the cervical and thoracolumbar spine, and it is under consideration for approval in the joint arthroplasty and dental fields. Scientists and engineers have made great strides in expanding the use of Si3N4 for clinical applications and addressing various issues being faced by the industry today. Si3N4 has the potential to be microstructurally engineered and adapted to many applications, e.g., by grain size and morphology, grain boundary phase, or in a composite. We expect that further innovation of Si3N4 will come soon.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9224221/

SintX is a fake it , till you make it scam - designed to fleece shareholders of there money. Here is why :

Potential Red Flags:

Overly ambitious promises: Sintx Technologies may have made grandiose claims about their technology's capabilities, potential market impact, and rapid growth.
Lack of transparency: The company might have been reluctant to disclose key details about its operations, financials, or product development.
Reliance on hype: Sintx Technologies may have heavily relied on marketing and public relations to create a positive image, rather than focusing on delivering a substantial product or service.
Limited tangible achievements: Despite the hype, the company may have struggled to demonstrate concrete milestones or tangible results.

1. Si3N4 as a Miracle Cure

Scientific skepticism: While Si3N4 has shown promise in certain applications, claiming it can "kill most bacteria and at least the most prevalent fungi" without further research and testing is premature. It's essential to conduct rigorous scientific studies to understand its efficacy, potential side effects, and compatibility with various materials.
Regulatory hurdles: Approving new medical technologies, especially those with antimicrobial properties, involves stringent regulatory processes. The FDA and other health authorities have strict guidelines to ensure safety and effectiveness. It's unlikely that any product could be rushed to market without thorough testing and documentation.
2. WWIII and Pandemic Predictions

Unfounded speculation: Predicting the occurrence of major world events like a third world war or a pandemic is highly speculative and often based on fear-mongering. While it's prudent to be prepared for unforeseen challenges, basing business decisions on such uncertain and unproven predictions is risky.
Solar Extrema and Pandemics: The claim that pandemics are connected to solar extrema lacks scientific evidence. There's no established causal link between solar activity and the emergence of infectious diseases. Such correlations are often coincidental and can be misleading.
3. Sintx, Zimmer Biomet, and IP

Business motivations: While it's true that companies often seek to diversify their product portfolios, suggesting that Zimmer Biomet would want Sintx's IP primarily due to potential war or pandemic-related benefits is overly simplistic. There are numerous factors influencing corporate decisions, including market demand, technological advancements, and competitive landscape.
Impact on business: While pandemics and wars can undoubtedly disrupt businesses, it's important to note that many companies have shown resilience and adaptability in the face of such challenges. By implementing appropriate strategies and contingency plans, businesses can mitigate the negative impacts and capitalize on opportunities.
Conclusion

The claims presented in the conspiracy theories are largely unsubstantiated and based on speculative assumptions. While it's reasonable to explore potential applications of Si3N4 in wound care and catheter materials, it's crucial to approach such developments with a scientific and evidence-based perspective. It's also important to avoid relying on fear-mongering and unfounded predictions to guide business decisions. By maintaining a balanced and informed approach, we can better assess the potential benefits and risks associated with new technologies and market trends.

Those problems present an enormous opportunity for Sintx and its partner(s) in the wound care/catherter markets. Imbuing wound care materials with Si3N4 will kill most bacteria and at least the most prevalent fungi like Candida. Coating catheters should do the same thing. However these things will take time to get to market with more testing and FDA submissions required. Thus its past-time for Sintx partner(s) in these two markets to step up, especially if WWIII is forthcoming.
If war is coming, along with another Pandemic, then its also past-time for PPE/protective apparel to get moving. If im correct about Solventum and Cardinal Health, then these two need to STEP-UP!

Global Catheter market = $55bn
Wound Care market = $22.25bn
Personal Protective Equipment market = $79.53 billion

Bill Gates says the world is facing two options: A ‘major war’ or another pandemic in less than 30 years
He cited “a lot of unrest” in the world at the moment, which could spark “a major war.”

But even if that conflict is avoided, “then yes, there will be another pandemic, most likely in the next 25 years,” Gates told CNBC Make It
There will definitely be another pandemic regardless if war occurs. Pandemics are connected to Solar Extrema. Thats why Monkeypox has been growing around Solar Max and the worst of Covid occurred around Solar Min.

Its unfortunate that war and pandemics would be good for Sintx but it also another reason why Zimmer Biomet would want the IP. Not only for diversification purposes but also because pandemics and war will hurt its business as was seen during COVID pandemic.


https://i.imgur.com/GUgo3Bb.png

Quote Source:
https://fortune.com/2024/09/10/bill-gates-fears-major-war-global-pandemic/

More on Solar Extrema and pandemics can be found here:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175031022

Counterargument 1: Existing medical device giants may have their own Si3N4 research initiatives.

Rebuttal: While it's certainly possible, Sintx's decades of research, extensive patent portfolio, and unique formulations give them a significant competitive advantage. Developing Si3N4-based medical devices from scratch would be a costly and time-consuming endeavor for larger companies, especially given the potential challenges in replicating Sintx's proprietary technology.
Counterargument 2: Competition could lead to fierce price wars.

Rebuttal: While competition can sometimes lead to price wars, Sintx's unique value proposition and strong intellectual property position it well to withstand such pressures. Their focus on niche markets and premium products can help differentiate their offerings and maintain profitability, even in a competitive environment.
Counterargument 3: Collaboration with companies like Solventum doesn't guarantee product adoption.

Rebuttal: While partnerships don't guarantee success, they can significantly accelerate market penetration and reduce risks. Collaborating with established players like Solventum provides access to distribution channels, regulatory expertise, and clinical trials, which can be invaluable in bringing new medical technologies to market.
Counterargument 4: The wound care and catheter markets are not as difficult to enter.

Rebuttal: While these markets may seem less competitive than the ortho device industry, they still have their own unique challenges. Regulatory hurdles, reimbursement issues, and the need to demonstrate clinical efficacy and safety can be significant barriers to entry. Sintx's expertise and technology give them a competitive edge in these markets.
Counterargument 5: Sintx needs to demonstrate its cost-effectiveness and long-term performance.

Rebuttal: Sintx is actively addressing these concerns through ongoing research and development. They are continuously working to optimize their manufacturing processes and reduce costs, while also conducting long-term studies to evaluate the durability and performance of their Si3N4-based products.
Conclusion

The potential of Sintx's Si3N4-based medical devices is undeniable. Their unique technology, strong intellectual property, and strategic partnerships position them well for long-term success. While there are challenges to overcome, the potential benefits of these devices in terms of improved patient outcomes and reduced healthcare costs make them a compelling investment.

Counterargument 1: The occurrence of chronic wounds is a major global health issue.

Rebuttal: While chronic wounds are a significant problem, it's important to note that they are often associated with underlying health conditions such as diabetes and circulatory disorders. Addressing these underlying issues is crucial for effective wound healing, and the role of bacteria and fungi may be overstated.
Counterargument 2: Bacteria and Fungi are a major issue for wound care leading to chronic wounds.

Rebuttal: While bacteria and fungi can contribute to chronic wound infections, other factors such as inadequate blood flow, pressure, and poor nutrition are often more significant. The focus on microbial control may be diverting attention from these underlying causes.
Counterargument 3: These exact problems are seen in the catheter industry.

Rebuttal: While catheter-related infections are a concern, it's important to acknowledge that preventive measures such as proper insertion techniques and antiseptic care can significantly reduce the risk of microbial contamination. The emphasis on microbial control may be overshadowing the importance of these preventive strategies.
Counterargument 4: Silicon Nitride is a promising material for medical applications.

Rebuttal: While silicon nitride has shown promise in certain medical applications, it's important to consider the potential limitations and challenges. For example, the long-term biocompatibility of silicon nitride in various tissues and environments needs to be further evaluated. Additionally, the manufacturing and processing of silicon nitride can be complex and expensive, which may limit its widespread adoption.
Conclusion

While the potential benefits of silicon nitride in medical applications are promising, it's crucial to maintain a balanced perspective and consider the limitations and challenges associated with its use. Overemphasizing the role of microbial control in chronic wound healing and catheter infections may divert attention from other important factors, such as underlying health conditions and preventive measures.

Debunking your Conspiracy Theories:

Counterargument 1: Existing medical device giants may have their own Si3N4 research initiatives or partnerships.

Rebuttal: While it's possible that larger medical device companies are conducting research on Si3N4, Sintx has a significant head start due to its decades of dedicated research and development. Their extensive patent portfolio and unique formulations would create significant barriers to entry for competitors. Furthermore, licensing Sintx's technology would likely be a more efficient and cost-effective strategy than attempting to replicate their research from scratch.
Counterargument 2: Competition could lead to fierce price wars, delaying Sintx's profitability.

Rebuttal: The current market for Si3N4-based medical devices is relatively small, with Sintx as a dominant player. While potential competition could lead to price pressure, Sintx's strong intellectual property and unique product offerings would provide a competitive advantage. Moreover, the company's focus on niche markets and value-added products could help mitigate the impact of price competition.
Counterargument 3: Collaboration with companies like Solventum doesn't guarantee product adoption.

Rebuttal: While there is no guarantee of product adoption, collaborations with established players like Solventum can provide significant benefits, such as access to distribution channels, regulatory expertise, and clinical trials. These partnerships can accelerate market penetration and increase the likelihood of commercial success.
Counterargument 4: The wound care and catheter markets are not as difficult to enter as the ortho device industry.

Rebuttal: While the wound care and catheter markets may be less competitive than the ortho device industry, they still present significant challenges. Sintx will need to demonstrate the clinical efficacy and cost-effectiveness of its Si3N4-based products in these markets to gain traction. Additionally, regulatory hurdles and reimbursement issues can also impact market entry and growth.
Counterargument 5: Sintx needs to demonstrate its cost-effectiveness and long-term performance compared to established materials.

Rebuttal: Sintx is actively working to address these concerns. The company has been investing in research and development to improve the manufacturing process and reduce costs. Additionally, Sintx is conducting long-term studies to evaluate the durability and performance of its Si3N4-based products in real-world clinical settings.
Conclusion

While it's important to maintain a critical eye and consider potential risks, the evidence strongly supports the potential of Sintx's Si3N4-based medical devices to revolutionize the industry. The company's unique technology, strong intellectual property, and strategic partnerships position it well for long-term success.

The occurrence of chronic wounds is a major global health issue. These wounds are difficult to heal as a result of disordered healing mechanisms. The most common types of chronic wounds are diabetic ulcers, pressure ulcers, arterial/venous ulcers and nonhealing surgical wounds. Although bacteria are an important cause of chronic nonhealing wounds, fungi also play a substantial role in them. The fungal infection rate varies with different chronic wound types, but overall, the prevalence of fungi is extremely underestimated in the clinical treatment and management of chronic wounds.
Bacteria and Fungi are a major issue for wound care leading to chronic wounds. Yet Silicon Nitride kills various bacteria and fungi which means the material embedded in wound care applicators could significantly reduce these problems.

These exact problems are seen in the catheter industry as well and thus both industries need effective anti bacterial/fungal products.

Microbe entry through catheter ports can lead to biofilm accumulation and complications from catheter-related bloodstream infection and ultimately require antimicrobial treatment and catheter replacement. Although strides have been made with microbial prevention by applying standardized antiseptic techniques during catheter implantation, both bacterial and fungal microbes can present health risks to already sick individuals.


Quote Sources:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9874004/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10258325/

========================================

Section 2 - Silicon Nitride, a Close to Ideal Ceramic Material for Medical Application

examples of their medical applications that relate to spinal, orthopedic and dental implants, bone grafts and scaffolds, platforms for intelligent synthetic neural circuits, antibacterial and antiviral particles and coatings, optical biosensors, and nano-photonic waveguides for sophisticated medical diagnostic devices are all covered in the research reviewed herein. The examples provided convincingly show that silicon nitride is destined to become a leader to replace titanium and other entrenched biomaterials in many fields of medicine.
https://www.mdpi.com/2571-6131/4/2/16/htm

Existing medical device giants might have their own Si3N4 research initiatives or partnerships with other companies.
Competition could lead to fierce price wars, delaying Sintx's profitability.
First off there is no competition in regards to Si3n4 at this time. Could there be one day, possibly. They can research Si3N4 but they'll have to come up with alternative formulation as Sintx patents would keep them from pursing much without Sintx. Honestly its easier for companies to simply license the tech than try to develop alternative formations in the shorter-term. Sintx been at this for decades.

Collaboration with companies like Solventum doesn't guarantee product adoption.
Nothings guaranteed except death. Solventum may not even be a partner but i find that unlikely as I doubt Hanson would want to compete against products with Si3n4 embedded in them. The reason the products will succeed is because of Si3N4's ability to kill bacteria and fungi which is a problem in both the catheter & wound care markets. Wound care and catheter markets are not likely as hard to enter as ortho device industry. That could be another reason for coatings to bridge the gap. Easier to get a coating cleared than a full implant and coatings can be applied to Sintx various "competitors" implants imparting those implants with the benefits of Si3n4.

While research indicates the potential of Si3N4, Sintx needs to demonstrate its cost-effectiveness and long-term performance compared to established materials.Switching to new materials requires strong clinical data and surgeon buy-in, which could take time.
The beauty of their coating products is they can be added to their competitor implants and thus do not have to replace those materials right away. However replacing those materials is something that needs to occur as soon as possible as the earths magnetic field is weakening and thus exposing metal implants to greater radiation and potential corrosion leading to biological disease.

When compounded with or applied to the surface of conventional inert biomaterials, silicon nitride’s improved osseointegration and resistance to bacterial colonization can be conferred to the resulting device. Another benefit of the coating method is that it allows for potential refinishing of existing devices to upgrade their functionality. Other filings in progress protect similar approaches to applying silicon nitride to metallic and polymeric substrates as part of SINTX’s broader strategy of expanding the applications where silicon nitride’s benefits can be realized.
https://ir.sintx.com/news-events/press-releases/detail/236/sintx-receives-notice-of-allowance-for-united-states-patent

While the potential of Sintx's technology is intriguing, let's explore some reasons why it might not translate to immediate dominance in the medical device space.

1. Partnerships Don't Guarantee Success:

Collaboration with companies like Solventum doesn't guarantee product adoption. Solventum might have other established suppliers or choose to develop their own Si3N4 technology.
Sintx relies on partners' expertise and marketing resources for product success. If a partner decides not to fully commit, it could stall product development or limit market reach.
2. Sintx Isn't the Only Player:

Existing medical device giants might have their own Si3N4 research initiatives or partnerships with other companies.
Competition could lead to fierce price wars, delaying Sintx's profitability.
3. Regulatory Hurdles:

Getting new medical devices (especially with novel materials) approved by the FDA can be a lengthy and expensive process.
Delays in regulatory approval could postpone Sintx's entry into these lucrative markets.
4. Unproven Advantages:

While research indicates the potential of Si3N4, Sintx needs to demonstrate its cost-effectiveness and long-term performance compared to established materials.
Switching to new materials requires strong clinical data and surgeon buy-in, which could take time.
5. Legal Concerns:

The claim that Sintx has "over 100 patents pending" might not fully address the issue of competition.
Other companies could develop workarounds or alternative materials that don't infringe on Sintx's patents.
Alternative Considerations:

Investigate the specific terms of Sintx's partnerships and their commitment to developing Si3N4 products.
Analyze the competitive landscape in each potential market Sintx is targeting.
Research the current regulatory environment for Si3N4-based medical devices.
A Word of Caution:

The quote from Dr. Bal about large companies acquiring smaller ones "to de-risk IP" is a possibility, but not a guarantee. Many smaller companies remain independent for years without acquisition.

Remember, the medical device market is highly regulated and competitive. While Sintx presents exciting technology, it may face a long and challenging path to becoming a dominant player.

NEW OPPORTUNITIES/MARKETS/PRODUCTS
Several new collaborations in developing products for wound care, cancer treatment, and an antipathogenic coating for catheters.
All three markets mentioned here from Jan presentation are markets that Solventum sells products in.

I bring up Solventum because Zimmer Biomets former CEO Bryan Hanson is now CEO of Solventum and knows all about Sintx IP from his Zimmer days
Bryan Hanson & 3M's Solventum
wound care, oral care, health care IT, and biopharma filtration
Quote Source:
https://d1io3yog0oux5.cloudfront.net/_9be13c70ea13288f968a56d0f02f5862/sintx/db/443/4298/pdf/SINTX+Corporate+Overview+-+Jan+%2724+-+Rev+J.pdf
https://news.3m.com/2023-08-22-Bryan-Hanson-Named-CEO-of-3Ms-Health-Care-Business-Group
https://www.3m.com/3M/en_US/medical-us/solutions/catheter-movement/

========================================

Section 2 - Silicon Nitride, a Close to Ideal Ceramic Material for Medical Application

examples of their medical applications that relate to spinal, orthopedic and dental implants, bone grafts and scaffolds, platforms for intelligent synthetic neural circuits, antibacterial and antiviral particles and coatings, optical biosensors, and nano-photonic waveguides for sophisticated medical diagnostic devices are all covered in the research reviewed herein. The examples provided convincingly show that silicon nitride is destined to become a leader to replace titanium and other entrenched biomaterials in many fields of medicine.
https://www.mdpi.com/2571-6131/4/2/16/htm


========================================

Section 3 - PioneerPhoenix73 has some misinformation in its post, purposeful or not. Some factual corrections needed in its post:

1. Zimmer Biomet did not acquire Implex as Zimmer Biomet did not exist in 2003. Zimmer acquired Implex 12 years before Zimmer became Zimmer Biomet.
2. Implex material was porous version of tantalum metal it called Hydrocel and Zimmer calls Trabecular Metal. Completely different material and a metal not ceramic.
3. Sintx tech is heavily patented making it very difficult for a partner company to steal its tech. As well as any partnership agreement would likely have extra clauses to prevent such a scenario. The scenario is highly unlikely in Western countries.
4. Sintx is the only company with medical grade Si3n4 with over 100 patents pending worldwide making it unlikely that Zimmer Biomet could license the tech from any other company. Furthermore testing of products related to Sintx and Biomet IP were tested in 2016, & 2018 showing further collaberation well after that 2011 quote. Zimmer Biomet even hired a Si3N4 coatings expert end of 2018 showing continued interest past 2018. Large companies like Zimmer Biomet use small companies like Sintx to de-risk IP and then acquire it. Thats exactly how J&J operates. Does that guarantee anything? No it does not. However according to one scientist, Silicon Nitride is destined to replace current materials used in many fields of medicine.
These are risk-averse companies that look to smaller companies like us to develop an idea, uh, and, uh, de-risk it, so to speak, and then buy that technology. ~ Dr Sonny Bal former CEO of Sintx.

In Figure 1, you can see J&J makes most of its money from pharmaceuticals and medical devices. They have grown these two sectors over the past decade through major capital investments in acquisitions and people development. Instead of investing in developing technology in-house, they use their size to acquire smaller companies who they believe have a promising trajectory in the healthcare space.
We believe we are the only FDA-registered and ISO 13485:2016 certified silicon nitride medical device manufacturing facility in the world, and the only provider of structural ceramics-based medical devices used for spinal fusion applications

Quote Sources:

https://web.archive.org/web/20240408152758/https://sintx.com/wp-content/uploads/2021/03/Investor-Call-Transcript-033021.pdf
https://d3.harvard.edu/platform-rctom/submission/a-family-of-companies-johnson-johnson/
https://www.sec.gov/ix?doc=/Archives/edgar/data/1269026/000149315224011546/form10-k.htm pg 7

1. Zimmer Biomet Acquisition of Implex Doesn't Guarantee Similar Outcome for Sintx:

The orthopaedic market landscape has changed significantly since 2003, when Zimmer acquired Implex. Competition may be fiercer, and alternative materials like highly cross-linked polyethylene might be more established.
Implex might have had a broader or more specific Si3N4 technology portfolio compared to Sintx, making a direct comparison difficult.
2. Partner Dependence Can Be a Double-Edged Sword:

Relying on partners for commercialization can limit Sintx's control over pricing, marketing, and distribution strategies.
Partner interests might not always align with Sintx's own goals. If a partner develops its own Si3N4 technology, they might prioritize it over Sintx's.
3. Hiring Former Employees Doesn't Guarantee Technology Transfer:

While these hires might have experience in relevant industries, their knowledge might be specific to their former employers' processes and technologies.
Legal restrictions might prevent them from directly transferring confidential information from their previous roles.
4. Zimmer Biomet's Past Interest Doesn't Guarantee Future Plans:

The 2011 quote about Zimmer potentially acquiring Amedica for licensing suggests their strategy might have shifted. They might be focusing on internal development or alternative partners.
Zimmer might have already licensed the key Si3N4 technology they need from Sintx and be less interested in further collaboration.
Alternative Considerations:

Look into the specific terms of any existing partnerships between Sintx and these companies. Are they licensing agreements, joint ventures, or something else?
Research the current market share and growth projections for Si3N4 in various industries beyond orthopaedics.
Analyze Sintx's own financial performance and ability to secure future partnerships to achieve its revenue goals.
By examining these points, you can build a more balanced perspective on Sintx's value proposition. Remember, past connections don't guarantee future success.

Zimmer Biomets mentioned for two main reasons and it is not to illustrate Sintx value. To demonstrate Sintx value, you look at Implex for a comparable materials company to get an idea of Si3n4's worth within the ortho industry only; ~230m based on a market that was 1/3rd the size it is today. You look at the industries the IP can be used in. Lastly you look at the partners Sintx appears to be working with to help it potentially commercialize its products in those industries.
One of the main reasons for mentioning Zimmer Biomet is this, to show that Sintx has large partnership to help it commercialize its products and that this particular company has been working with Sintx for going on 20 years. Sintx partnerships are key to its success due to how Sintx is setup to generate revenue: license its IP/supply blanks/powder as i said in a previous post. Its not setup to sell direct to market. This reduces costs and risk of scaling operations while also reducing maximum potential revenue. However that makes it very dependent on its partners. Thats why i used a scenario of 5% licensing fee and 5% penetration of markets that are well over 300bn in size to come up with 800m in revenue. Sintx, with its partners should be able to penetrate several of those markets far greater than 5% but i used that as an average across all those industries.
Below shows the connections to Zimmer Biomet & Morgan Ceramics/NP Aerospace. I bring up Solventum because Zimmer Biomets former CEO Bryan Hanson is now CEO of Solventum and knows all about Sintx IP from his Zimmer days. Thus i could see Solventum being one of Sintx partners in relation to Wound Care & possibly cancer related products via biofarma filtration using Si3n4 based membrane. I bring up Cardinal Health because of Sintx hire of Joseph Palomo who came from Cardinal Health R&D division. Again a potential partner in relation to PPE & Catheters.
Sintx has a pattern of hiring individuals from large companies it works with like Zimmer Biomet, possibly Cardinal Health, Morgan Ceramics. Those hires all seem to come to Sintx to help it set itself up to supply products in the same industries those companies operate in. Thus i strongly suspect they join to get Sintx ready to supply the company they came from.

Cardinal Health
Palomo joins SINTX with over 40 years of experience in protective apparel and PPE, such as surgical gowns, surgical drapes, isolation gowns, films, tubing, and surgical face masks.
https://ir.sintx.com/news-events/press-releases/detail/184/sintx-technologies-provides-update-on-antipathogenic

Bryan Hanson & 3M's Solventum
wound care, oral care, health care IT, and biopharma filtration
https://news.3m.com/2023-08-22-Bryan-Hanson-Named-CEO-of-3Ms-Health-Care-Business-Group

Ultrathin silicon nitride membrane with slit-shaped pores for high-performance separation of circulating tumor cells
https://pubmed.ncbi.nlm.nih.gov/35997043/

========================================

A basic roadmap laid out of Zimmer's intentions for Sintx back in 2011. This quote predates Sintx vast IP portfolio expansion. Any markets Zimmer Biomet does not currently participate in, that Sintx does, represents potential markets Zimmer Biomet can utilize Sintx to bolster its revenue through licensing as well as diversify those revenue sources.
AnonymousMay 24, 2011 at 3:42 PM
Zimmer is looking at purchasing Amedica flat out for their techology to bolster sales in spine through licensing and to purchase the next generation of hip and knee implants. You heard it here on TSB.
https://web.archive.org/web/20240408163612/https://spineblogger.blogspot.com/2011/05/whos-next.html?m=1

Silicon Nitride = Next Gen Hip implant material

Silicon nitride, silicon carbide and diamond-like carbon as non-oxide ceramics are considered to be the new generation of materials used in hip prosthetics
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10422432/

Sintx - Zimmer Personel Connection
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174053353

Sintx - Zimmer connection purposefully not disclosed/removed from 2013 IPO paperwork?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174144294

Sintx - Biomet R&D
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174053136

Sintx Intellectual Property is worth more than $230m as shown by Zimmers acquisition of Implex in 2003
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174493456:

Dr. Pezzotti member of Sintx scientific board and his research for Biomet
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174052660

Zimmer Biomet Hires Si3N4 Coatings Expert for its anti-infective dvision - December 2018
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174115529

Zimmer Biomet pays 2.5m certain R&D payment Q2 2017, Dr Bal's investment company loans $2.5m to Sintx.Q3, 2017
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174152867

Sintx - Morgan Ceramics partnership & NP Aerospace Connections
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174166246
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174166439


Mr Bond, they have a saying in Chicago: 'Once is happenstance. Twice is coincidence. The third time it's enemy action'.
One is an incident, two is a coincidence, three's a pattern, and four is enough for a warrant

"While it's understandable to be skeptical about the complexities of the stock market, the claim that it's entirely controlled by a secret cabal of shadowy figures and manipulated by AI is a harmful and unfounded conspiracy theory. While there have been instances of market manipulation and insider trading, these are illegal activities that are actively investigated and prosecuted by regulatory authorities. The stock market is influenced by a variety of factors, including economic indicators, company performance, investor sentiment, and global events. While AI is increasingly used in financial analysis and trading, it's important to remember that it's a tool that is used by many different participants, not a single entity controlling the market. It's crucial to base our understanding of the stock market on factual information and avoid perpetuating harmful conspiracy theories."

What does scientific research or valid research have to do with anything. You can compete with someone who thinks there gods messenger trying to save the world from non existence phenomena or others that think shutting off there wifi makes them sleep better at night.

SintX has become a poster child for insanity. What about implants in big toes and dental implants being sensitive to EM ?

LOL!!!!!!


Then there's the "manipulation" theory. It's almost as if someone is trying to convince you that the stock market is a rigged game controlled by a secret cabal of shadowy figures

NEWSFLASH that is exactly what it is.... an AI manipulated hot mess.

Any "scientific research" that does not compensate for neutrogenic toxins distiributed during the COVID B.S. Is propaganda and not valid research.

lt has nothing to do wyouth your research...

It is about AI pump and dump.


TRYIN TO MAKE IT REAL.... compared to what...

Zimmer Biomets mentioned for two main reasons and its not to illustrate Sintx value. To demonstrate Sintx value, you look at Implex for a comparable materials company to get an idea of Si3n4's worth in the ortho industry. You look at the industries the IP can be used in. Lastly you look at the partners Sintx appears to be working with to help it potentially commercialize its products in those industries. One of the main reasons for mentioning Zimmer Biomet is this, to show that Sintx has large partnership to help it commercialize its products and that this particular company has been working with Sintx for going on 20 years. Sintx partners are important due to how Sintx is setup to generate revenue: license its IP/supply blanks/powder as i said in my last post. Its not setup to sell direct to market. This reduces costs and risk of scaling operations while also reducing maximum potential revenue. However that makes it very dependent on its partners. Thats why i used a scenario of 5% licensing fee and 5% penetration of markets that are well over 300bn in size to come up with 800m in revenue. Sintx, with its partners should be able to penetrate several of those markets far greater than 5% but i used that as an average across all those industries.
Below shows the connections to Zimmer Biomet & Morgan Ceramics/NP Aerospace. I bring up Solventum because Zimmer Biomets former CEO Bryan Hanson is CEO of Solventum and knows all about Sintx IP from his Zimmer's days. Thus i could see Solventum being one of Sintx partners in relation to PPE, catheter, &/or wound care. I bring up Cardinal Health because of Sintx hire of Joseph Palomo who came from Cardinal Health R&D division.
Sintx has a pattern of hiring individuals from large companies it works with like Zimmer Biomet, possibly Cardinal Health, Morgan Ceramics. Those hires all seem to come to Sintx to help it set itself up to supply products in the same industries those companies operate in. Thus i strongly suspect they join to get Sintx ready to supply the company they came from. Cardinal Health could be another PPE and wound care oriented partner. Solventum or Cardinal health could be working with Sintx on products for Cancer as well as a company is working with Sintx on cancer products. This could be connected to the biosensor market mentioned in my list o potential markets.

Cardinal Health
https://ir.sintx.com/news-events/press-releases/detail/184/sintx-technologies-provides-update-on-antipathogenic

Bryan Hanson & 3M's Solventum
https://news.3m.com/2023-08-22-Bryan-Hanson-Named-CEO-of-3Ms-Health-Care-Business-Group

========================================

A basic roadmap laid out of Zimmer's intentions for Sintx back in 2011. This quote predates Sintx vast IP portfolio expansion. Any markets Zimmer Biomet does not currently participate in, that Sintx does, represents potential markets Zimmer Biomet can utilize Sintx to bolster its revenue through licensing as well as diversify those revenue sources.
AnonymousMay 24, 2011 at 3:42 PM
Zimmer is looking at purchasing Amedica flat out for their techology to bolster sales in spine through licensing and to purchase the next generation of hip and knee implants. You heard it here on TSB.
https://web.archive.org/web/20240408163612/https://spineblogger.blogspot.com/2011/05/whos-next.html?m=1

Silicon Nitride = Next Gen Hip implant material

Silicon nitride, silicon carbide and diamond-like carbon as non-oxide ceramics are considered to be the new generation of materials used in hip prosthetics
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10422432/

Sintx - Zimmer Personel Connection
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174053353

Sintx - Zimmer connection purposefully not disclosed/removed from 2013 IPO paperwork?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174144294

Sintx - Biomet R&D
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174053136

Sintx Intellectual Property is worth more than $230m as shown by Zimmers acquisition of Implex in 2003
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174493456:

Dr. Pezzotti member of Sintx scientific board and his research for Biomet
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174052660

Zimmer Biomet Hires Si3N4 Coatings Expert for its anti-infective dvision - December 2018
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174115529

Zimmer Biomet pays 2.5m certain R&D payment Q2 2017, Dr Bal's investment company loans $2.5m to Sintx.Q3, 2017
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174152867

Sintx - Morgan Ceramics partnership & NP Aerospace Connections
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174166246
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174166439


Mr Bond, they have a saying in Chicago: 'Once is happenstance. Twice is coincidence. The third time it's enemy action'.
One is an incident, two is a coincidence, three's a pattern, and four is enough for a warrant

Since Zimmer is mentioned on this board nonstop, it would be interesting if Zimmer EVER mentions Sintx OR if any OTHER posters on the Zim board mention Sintx. Just saying, as I have zero interest in doing research on the matter, but have seen MANY times, small companies (and their followers) mention the big guys and their connections to them (alleged, potential, small, and imaginary large), in order to show their own values....which never seem to arrive.